<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848419</url>
  </required_header>
  <id_info>
    <org_study_id>Exp pain 1-ginosar-HMO-CTIL</org_study_id>
    <nct_id>NCT00848419</nct_id>
  </id_info>
  <brief_title>A Prospective Randomized Comparison of Fentanyl, Methadone and Morphine for Epidural Analgesia in an Experimental Pain Model</brief_title>
  <official_title>A Prospective Randomized Comparison of Fentanyl, Methadone and Morphine for Epidural Analgesia in an Experimental Pain Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to provide pharmacokinetic-pharmacodynamic data to quantify the
      analgesic and side effect profiles of epidural methadone, fentanyl and morphine. The
      investigators will compare the analgesic effect at three dermatomes to assess the rostral
      spread of drug, the investigators will assess plasma levels to assess the systemic
      redistribution of drug and the investigators will assess surrogate markers of central opiate
      effects (nasal capnography and pupilometry). The investigators hypothesize that due to the
      long-duration of action of methadone, and its intermediate lipophilicity, that methadone will
      provide a predominantly segmental analgesia of long duration of action, with low rostral
      spread and low direct central depressant effects (including respiratory depression).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in heat pain tolerance from baseline (using QST Medoc)</measure>
    <time_frame>At intervals: 30, 60, 90, 120, 180, 240, 300, 360, 410 min following drug and 24 hours following drug.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in electrical pain tolerance from baseline</measure>
    <time_frame>At same time intervals as primary outcome</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of methadone, fentanyl, morphine (and metabolites)</measure>
    <time_frame>At each of the time intervals as for primary endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupilometry</measure>
    <time_frame>At each of the time intervals as primary endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate and arterial CO2 tension</measure>
    <time_frame>At each of the time intervals as primary endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epidural methadone bolus 4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epidural morphine 4mg bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epidural fentanyl 200 microgram bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Epidural saline bolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural administration of bolus</intervention_name>
    <arm_group_label>Methadone</arm_group_label>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (men and women) scheduled for extracorporeal shock wave lithotrypsy (for
             nephrolithiasis) under regional anesthesia.

        Exclusion Criteria:

          -  Inability to understand consent form; poor communication Refusal to sign consent form
             Contraindication to regional anesthesia Chronic opioid administration ASA
             classification 3 or greater Age &lt; 18 or &gt; 70
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Elyad Davidson, Director, Pain Unit</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Epidural</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Methadone</keyword>
  <keyword>Morphine</keyword>
  <keyword>Pharmacokinetic-pharmacodynamic</keyword>
  <keyword>Experimental pain - analgesic response</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

